profit from every $100 of sales.
$0$100
Integra LifeSciences
$14.77+1.65% today
+19.8% in 1 year
1-year low $8.901-year high $19.85
Trading in the middle of its range for the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average, 2022 to 2025.
0%20% a year
It has no yearly profit to compare the price with.
CheapExpensive
of earnings would pay off all its debt.
No debt5 years
Money in, money out
What Integra LifeSciences sold, what it kept, and what it did with the cash.
Sales went from $1.56 billion in 2022 to $1.64 billion in 2025, with -$516 million of profit last year.
SalesProfit
Integra LifeSciences vs. similar companies
How it compares with the largest companies in its industry.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| Integra LifeSciences | No profit yet | ||
 Boston Scientific | 22.6× · Fair price | ||
 Koninklijke Philips | 29.7× · Fair price | ||
 Steris | 31.8× · Expensive | ||
 Zimmer Biomet Holdings | 28.8× · Fair price |
AI analysis
An AI analyst reads Integra LifeSciences's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 1,558 | 1,542 | 1,611 | 1,635 | |
| 970 | 885 | 882 | 832 | |
| 239 | 112 | 28 | 18 | |
| 382 | 256 | 193 | -325 | |
| 181 | 68 | -7 | -516 | |
| 2.16 | 0.84 | -0.09 | -6.74 | |
| 62.3% | 57.4% | 54.8% | 50.9% | |
| 15.3% | 7.2% | 1.8% | 1.1% | |
| 11.6% | 4.4% | -0.4% | -31.6% |
Balance sheet
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total assets | 3,890 | 3,782 | 4,037 | 3,602 |
| Cash | 457 | 276 | 246 | 235 |
| Total debt | 1,615 | 1,682 | 1,985 | 2,033 |
| Total liabilities | 2,085 | 2,194 | 2,492 | 2,559 |
| 1,804 | 1,588 | 1,545 | 1,043 | |
| 84 | 80 | 77 | 78 | |
| 6.1% | 3.2% | 1.2% | -12.3% | |
| 10.0% | 4.3% | -0.4% | -49.5% |
Cash flow
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 264 | 140 | 129 | 50 | |
| 47 | 67 | 114 | 96 | |
| 217 | 73 | 15 | -45 | |
| Dividends paid | – | – | – | – |
| 125 | 275 | 52 | 0 | |
| 28 | 20 | 24 | 19 |
Valuation
- –
- 6.3×
- –
- 1.1×
- 0.7×
- –
- –
- -3.9%
- -45.0%
- 0.0%
Profitability
- 50.9%
- 1.1%
- -31.6%
- -16.6%
- 3.5%
- -0.9%
- -47.6%
- -13.9%
- 3.8%
- 5.9%
Growth
- +1.6%
- –
- −224.4%
- –
- −2.4%
Financial health
- –
- 1.96
- 57.0%
- 1.3×
- 3.38
- 1.95
- 0.46
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Bottom 42%of 959
Bottom 28%of 888
Bottom 21%of 889
Bottom 20%of 987
What analysts expect
- Average price target
- $12.00
- Range
- $12.00 – $12.00
- 1 analysts
These targets were collected on May 20, 2026 and our analyst feed has not updated since, so we no longer compare them with today's price.
Recent earnings
Our results feed has not updated since May 21, 2026. Results reported after that are not in this table yet.
| Date | EPS | Expected | Surprise |
|---|---|---|---|
| May 5, 2026 | 0.54 | 0.41 | +31.7% |
| Feb 26, 2026 | 0.83 | 0.79 | +5.1% |
| Oct 30, 2025 | 0.54 | 0.43 | +25.6% |
| Jul 31, 2025 | 0.45 | 0.43 | +4.7% |
| May 5, 2025 | 0.41 | 0.43 | −4.7% |
| Feb 25, 2025 | 0.97 | 0.86 | +12.8% |
| Nov 4, 2024 | 0.41 | 0.39 | +5.1% |
| Jul 29, 2024 | 0.63 | 0.62 | +1.6% |
News
Integra Resources Corp. Non-GAAP EPS of $0.06 in-line, revenue of $72.4M beats by $1.03MSeeking Alpha · Nov 11, 2026Integra LifeSciences Holdings Corporation Q3 2026 Earnings PreviewSeeking Alpha · Oct 20, 2026Integra LifeSciences prices $450M in 9.5% secured notesSeeking Alpha · Oct 9, 2026Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
0/7Passes 0 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
21No pass
Benjamin Graham
53No pass
Philip Fisher
32No pass
Peter Lynch
13No pass
Joel Greenblatt
0No pass
Charlie Munger
27No pass
Terry Smith
26No pass
Questions about Integra LifeSciences
Is Integra LifeSciences a good stock to buy?
A business with weak numbers that is not profitable yet. 0 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the Integra LifeSciences AI analysis
What does Integra LifeSciences do?
Integra LifeSciences Holdings Corporation develops, manufactures, and markets surgical implants and medical instruments for use in neurosurgery, extremity reconstruction, and general surgery. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. It is in Medical - Devices.
Does Integra LifeSciences pay a dividend?
No. Integra LifeSciences does not pay a dividend at the moment; in 2025 it returned $221,000 to shareholders by buying back its own shares.
Is Integra LifeSciences stock halal?
No. Integra LifeSciences does not pass our halal screen: its debt is 177% of its market value, at or above the 33% limit. How we check
How has Integra LifeSciences stock done over the past year?
Up 19.8% over the past twelve months, to $14.77. It traded between $8.90 and $19.85 and is 25.6% below its high.
Who are Integra LifeSciences's competitors?
The largest listed companies in the same industry are Boston Scientific, Koninklijke Philips, Steris and Zimmer Biomet Holdings. The peers table on this page compares their profit, growth and price with Integra LifeSciences's.
Prices: daily closes to Nov 11, 2026. Fundamentals: company reports via invest-like data.